search
Back to results

To Investigate the Absorption, Metabolism, Excretion, Absolute Bioavailability, and Immunogenicity of GX-I7 in Healthy Volunteers

Primary Purpose

Leukopenia

Status
Unknown status
Phase
Early Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
GX-I7 or [14C] GX-I7
Sponsored by
Seoul National University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Leukopenia

Eligibility Criteria

19 Years - 45 Years (Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Subject is willing and able to give informed consent after listening character of the clinical trial
  2. Must be 19-45 years of age, inclusive
  3. Weight 50-100kg, BMI 18-30kg/m2
  4. Subject who is adequately able to attend the study based on medical history and physical exam, no clinically significant abnormality from vital sign and clinical laboratory values
  5. No clinical abnormality from ECG test
  6. Non-smoker (no smoking or no use of any product containing nicotine least for one month and negative from urine test)

Exclusion Criteria:

  1. Suspected or confirmed malignancy, or has malignancy history
  2. Any clinically significant acute or chronic medical condition requiring care of a physician, in liver, biliary tract, renal, nervous system (CNS or peripheral). respiratory system, endocrine (diabetes, hyperlipidemia etc), cardiovascular (congestive heart failure, coronary artery disease, myocardial infarction etc), hematology, malignancy, urinary disease, mental disorder, musculoskeletal disorder, immune system (rheumatoid arthritis, lupus etc), otorhinolaryngologic diseases
  3. Positive to HBsAg, hepatitis C virus (HCV) Ab and HIV Ab
  4. Are considering or scheduled to undergo any surgical or dental procedure during the study
  5. Administered other Investigational Product (IP) by attending other clinical study or biological equivalent study within recent 6 months
  6. Any Serious adverse drug reaction (SAR) against vaccines or antibiotics, any medical history with serious allergic diseases
  7. Positive from urine drug screen or respiratory alcohol screen at medical screening
  8. History of alcohol, drug, or substance abuse in the past 12 months
  9. A heavy alchol consumer (>21 units/week, 1 unit = 10 g of pure alcohol) or Consumption of alcohol within 48 hours prior to hospitalization
  10. Medications with antacid, analgesic, herbal treatment, vitamin, mineral (except maximum 4 grams of acetaminophen) hormone, steroids, insulin, hypoglycemic drug or other hormone substitute within 14 days before administration
  11. Planning pregnancy or donation of sperm/disagreeing proper contraception during the study and 3 months following IP administration
  12. Do not have veins suitable for cannulation or multiple venipunctures
  13. Previously donate whole blood within 60 days or component blood within 14 days
  14. Excessive consumption of foods containing grapefruits
  15. Any other factor that the Investigator thinks will increase subject risk with participation

Sites / Locations

  • Seoul National University Hospital Clinical Trial Center

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Part 1

Part 2

Part 3

Arm Description

IM: GX-I7 60 µg/kg IV: [14C]-GX-I7 40 µg

IV: [14C]-GX-I7 40 µg

IM: GX-I7 60 µg/kg, [14C]-GX-I7 40 µg

Outcomes

Primary Outcome Measures

Total radioactivity at feces,urine,blood to measure total recovery rate
radioactivity in nCi

Secondary Outcome Measures

Full Information

First Posted
November 18, 2019
Last Updated
February 23, 2020
Sponsor
Seoul National University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04283695
Brief Title
To Investigate the Absorption, Metabolism, Excretion, Absolute Bioavailability, and Immunogenicity of GX-I7 in Healthy Volunteers
Official Title
A Phase 1, Open-labeled, Single-dose, One-sequence, One-period, 3-part Study to Investigate the Absorption, Metabolism, Excretion, Absolute Bioavailability, and Immunogenicity of GX-I7 in Healthy Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
February 2020
Overall Recruitment Status
Unknown status
Study Start Date
July 3, 2019 (Actual)
Primary Completion Date
August 30, 2019 (Actual)
Study Completion Date
May 1, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Seoul National University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
A Phase 1, open-labeled, single-dose, one-sequence, one-period, 3-part study to investigate the absorption, metabolism, excretion, absolute bioavailability, and immunogenicity of GX-I7 in healthy volunteers
Detailed Description
A Phase 1, open-labeled, single-dose, one-sequence, one-period, 3-part study to investigate the absorption, metabolism, excretion, absolute bioavailability, and immunogenicity of GX-I7 in healthy volunteers To show ABA and Mass balance of GX-I7

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leukopenia

7. Study Design

Primary Purpose
Basic Science
Study Phase
Early Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
12 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Part 1
Arm Type
Experimental
Arm Description
IM: GX-I7 60 µg/kg IV: [14C]-GX-I7 40 µg
Arm Title
Part 2
Arm Type
Experimental
Arm Description
IV: [14C]-GX-I7 40 µg
Arm Title
Part 3
Arm Type
Experimental
Arm Description
IM: GX-I7 60 µg/kg, [14C]-GX-I7 40 µg
Intervention Type
Drug
Intervention Name(s)
GX-I7 or [14C] GX-I7
Intervention Description
IM GX-I7 or IV/IM microdose of GX-I7
Primary Outcome Measure Information:
Title
Total radioactivity at feces,urine,blood to measure total recovery rate
Description
radioactivity in nCi
Time Frame
29 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Subject is willing and able to give informed consent after listening character of the clinical trial Must be 19-45 years of age, inclusive Weight 50-100kg, BMI 18-30kg/m2 Subject who is adequately able to attend the study based on medical history and physical exam, no clinically significant abnormality from vital sign and clinical laboratory values No clinical abnormality from ECG test Non-smoker (no smoking or no use of any product containing nicotine least for one month and negative from urine test) Exclusion Criteria: Suspected or confirmed malignancy, or has malignancy history Any clinically significant acute or chronic medical condition requiring care of a physician, in liver, biliary tract, renal, nervous system (CNS or peripheral). respiratory system, endocrine (diabetes, hyperlipidemia etc), cardiovascular (congestive heart failure, coronary artery disease, myocardial infarction etc), hematology, malignancy, urinary disease, mental disorder, musculoskeletal disorder, immune system (rheumatoid arthritis, lupus etc), otorhinolaryngologic diseases Positive to HBsAg, hepatitis C virus (HCV) Ab and HIV Ab Are considering or scheduled to undergo any surgical or dental procedure during the study Administered other Investigational Product (IP) by attending other clinical study or biological equivalent study within recent 6 months Any Serious adverse drug reaction (SAR) against vaccines or antibiotics, any medical history with serious allergic diseases Positive from urine drug screen or respiratory alcohol screen at medical screening History of alcohol, drug, or substance abuse in the past 12 months A heavy alchol consumer (>21 units/week, 1 unit = 10 g of pure alcohol) or Consumption of alcohol within 48 hours prior to hospitalization Medications with antacid, analgesic, herbal treatment, vitamin, mineral (except maximum 4 grams of acetaminophen) hormone, steroids, insulin, hypoglycemic drug or other hormone substitute within 14 days before administration Planning pregnancy or donation of sperm/disagreeing proper contraception during the study and 3 months following IP administration Do not have veins suitable for cannulation or multiple venipunctures Previously donate whole blood within 60 days or component blood within 14 days Excessive consumption of foods containing grapefruits Any other factor that the Investigator thinks will increase subject risk with participation
Facility Information:
Facility Name
Seoul National University Hospital Clinical Trial Center
City
Seoul
Country
Korea, Republic of

12. IPD Sharing Statement

Learn more about this trial

To Investigate the Absorption, Metabolism, Excretion, Absolute Bioavailability, and Immunogenicity of GX-I7 in Healthy Volunteers

We'll reach out to this number within 24 hrs